Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Conference call and webcast, August 07, 2019 at 3:00 pm CET, 9:00 am EST
NOXXON Pharma N.V. announced that following discussions with investors it has received letters of intent and binding commitments for long-term investment of €1 million through a private placement plus additional commitment for a future private placement.
Big Data falls short - the consulting company MAIN5 presents study “Pharma Insights 2019"
Orion Biotechnology Canada Ltd. announced that Sir Gregory Winter FRS has agreed to chair the Orion Biotechnology Scientific Advisory Board (SAB).
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Gene therapy companies could be continued M&A targets for larger ones as more and more companies are looking to broaden their therapeutic focus with potential one-time therapies for various diseases.
Permira initiated the transaction after Cambrex flexed its own M&A muscle and acquired Avista and Halo.
Oxford Immunotec Global PLC, or the Company, a global, high-growth diagnostics company, announced second quarter 2019 financial results.
Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology
The owners of Cytena GmbH have agreed to sell all Cytena shares to CELLINK AB for a purchase price of 30.25M euros.